Maintenance therapy with recombinant interferon alpha-2B (αIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL)

G. Palmieri, A. Morabito, A. Rea, R. Lauria, V. Montesarchio, E. Biondi, M. Caraglia, P. Tagliaferri, A. R. Blanco

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Fifteen patients from a series of 37 consecutive patients with aggressive NHL who achieved a complete remission (CR) with first line chemotherapy were defined at high or high-intermediate risk of relapse according to International Prognostic Risk Index and were treated with αIFN as maintenance therapy for two years. After a median follow-up of 62 months only 3/15 patients (20%) relapsed and 2/15 (13.3%) died in the αIFN treated group, favourably comparing with the expected relapse and death rate in that setting; on the other hand 40.9% of 'low risk' patients from the same series, who did not receive αIFN, had relapsed. αIFN maintenance therapy appears to result in prolonged response duration and survival in patients with aggressive and prognostically unfavourable NHL.

Original languageEnglish
Pages (from-to)733-735
Number of pages3
JournalOncology Reports
Volume3
Issue number4
Publication statusPublished - 1996

Fingerprint

interferon alfa-2b
Non-Hodgkin's Lymphoma
Therapeutics
Recurrence
Drug Therapy

Keywords

  • aggressive non-Hodgkin's lymphoma
  • alpha-interferon
  • prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Maintenance therapy with recombinant interferon alpha-2B (αIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL). / Palmieri, G.; Morabito, A.; Rea, A.; Lauria, R.; Montesarchio, V.; Biondi, E.; Caraglia, M.; Tagliaferri, P.; Blanco, A. R.

In: Oncology Reports, Vol. 3, No. 4, 1996, p. 733-735.

Research output: Contribution to journalArticle

Palmieri, G, Morabito, A, Rea, A, Lauria, R, Montesarchio, V, Biondi, E, Caraglia, M, Tagliaferri, P & Blanco, AR 1996, 'Maintenance therapy with recombinant interferon alpha-2B (αIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL)', Oncology Reports, vol. 3, no. 4, pp. 733-735.
Palmieri, G. ; Morabito, A. ; Rea, A. ; Lauria, R. ; Montesarchio, V. ; Biondi, E. ; Caraglia, M. ; Tagliaferri, P. ; Blanco, A. R. / Maintenance therapy with recombinant interferon alpha-2B (αIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL). In: Oncology Reports. 1996 ; Vol. 3, No. 4. pp. 733-735.
@article{fe561d4f930d4e268394d62e9ab101c9,
title = "Maintenance therapy with recombinant interferon alpha-2B (αIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL)",
abstract = "Fifteen patients from a series of 37 consecutive patients with aggressive NHL who achieved a complete remission (CR) with first line chemotherapy were defined at high or high-intermediate risk of relapse according to International Prognostic Risk Index and were treated with αIFN as maintenance therapy for two years. After a median follow-up of 62 months only 3/15 patients (20{\%}) relapsed and 2/15 (13.3{\%}) died in the αIFN treated group, favourably comparing with the expected relapse and death rate in that setting; on the other hand 40.9{\%} of 'low risk' patients from the same series, who did not receive αIFN, had relapsed. αIFN maintenance therapy appears to result in prolonged response duration and survival in patients with aggressive and prognostically unfavourable NHL.",
keywords = "aggressive non-Hodgkin's lymphoma, alpha-interferon, prognostic factors",
author = "G. Palmieri and A. Morabito and A. Rea and R. Lauria and V. Montesarchio and E. Biondi and M. Caraglia and P. Tagliaferri and Blanco, {A. R.}",
year = "1996",
language = "English",
volume = "3",
pages = "733--735",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Maintenance therapy with recombinant interferon alpha-2B (αIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL)

AU - Palmieri, G.

AU - Morabito, A.

AU - Rea, A.

AU - Lauria, R.

AU - Montesarchio, V.

AU - Biondi, E.

AU - Caraglia, M.

AU - Tagliaferri, P.

AU - Blanco, A. R.

PY - 1996

Y1 - 1996

N2 - Fifteen patients from a series of 37 consecutive patients with aggressive NHL who achieved a complete remission (CR) with first line chemotherapy were defined at high or high-intermediate risk of relapse according to International Prognostic Risk Index and were treated with αIFN as maintenance therapy for two years. After a median follow-up of 62 months only 3/15 patients (20%) relapsed and 2/15 (13.3%) died in the αIFN treated group, favourably comparing with the expected relapse and death rate in that setting; on the other hand 40.9% of 'low risk' patients from the same series, who did not receive αIFN, had relapsed. αIFN maintenance therapy appears to result in prolonged response duration and survival in patients with aggressive and prognostically unfavourable NHL.

AB - Fifteen patients from a series of 37 consecutive patients with aggressive NHL who achieved a complete remission (CR) with first line chemotherapy were defined at high or high-intermediate risk of relapse according to International Prognostic Risk Index and were treated with αIFN as maintenance therapy for two years. After a median follow-up of 62 months only 3/15 patients (20%) relapsed and 2/15 (13.3%) died in the αIFN treated group, favourably comparing with the expected relapse and death rate in that setting; on the other hand 40.9% of 'low risk' patients from the same series, who did not receive αIFN, had relapsed. αIFN maintenance therapy appears to result in prolonged response duration and survival in patients with aggressive and prognostically unfavourable NHL.

KW - aggressive non-Hodgkin's lymphoma

KW - alpha-interferon

KW - prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0029977339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029977339&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029977339

VL - 3

SP - 733

EP - 735

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -